Neuralstem Announces Presentation of Long-Term Follow Up Phase I Data in ALS Treatment Trial

Jonathan D. Glass, MD, site investigator at Emory University, recently presented long-term follow-up data regarding the Phase I trial testing of Neuralstem Inc's NSI-566 human neural stem cells in the treatment of amyotrophic lateral sclerosis . A Neuralstem news release notes that the presentation took place at the Annual Symposium on ALS of the Foundation Andre-Delambre, in Montreal, Canada, and was not open to the public.

http://ift.tt/1rg8F19